Announcement
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Presentation Details
| Evaluation of C-Reactive Protein in End-Stage Renal Disease Patients Neha Koganti1, Aarav Gupta1, Fakiha Siddiqui 2, Jawed Fareed2, Vinod Bansal2. 1Global Thrombosis Forum, Suwanee, GA, USA.2Loyola University, Maywood, IL, USA |
Abstract
Background: Inflammation is the immune system’s response to injury or infection. It is characterized by redness, heat, swelling, and pain. Inflammation plays a major role in the progression and complications of end-stage renal disease (ESRD), which is the final stage of chronic kidney disease. In ESRD, the kidneys lose nearly all their ability to perform essential functions, such as filtering waste products and regulating fluid levels. At this stage, the glomerular filtration rate is less than 15 mL/min/1.73m2. Because inflammation significantly impacts ESRD, biomarkers such as C-reactive protein (CRP) are frequently used to assess inflammation and predict patient outcomes. CRP is an acute-phase protein produced primarily by the liver in response to inflammation, and its synthesis is stimulated by cytokines, such as interleukin-6. Because of its rapid increase during inflammation and short half-life, CRP serves as a reliable and sensitive biomarker for inflammatory activity. Objectives: Our objective was to compare an inflammatory biomarker (specifically CRP) between healthy individuals and patients with ESRD, and to understand the relationship between inflammation and ESRD. Methods: A comparative study was performed using two groups: ESRD (n=72) and healthy controls (n=50). The ESRD group consisted of patients diagnosed with end-stage renal disease (glomerular filtration rate <15 mL/min/1.73 m2). The Healthy control group was individuals with no known inflammatory or renal disorders. Blood samples were collected from patients and analyzed by sandwich ELISA, and CRP levels were measured in µg/mL. Comparisons between the ESRD and control groups were performed using a Mann-Whitney U test, with an alpha value of 0.05. Results (Figure 1): The data were statistically significant (p-value <0.0001), indicating a correlation between ESRD patients and high CRP levels. Patients with ESRD had higher CRP levels, with a median of 6.366 (IQR: 2.306-11.75), than healthy (control) patients, with a median of 0.317 (IQR: 0.0105-1.173). Figure 1 shows higher CRP levels in ESRD patients overall, with median and IQR values also higher in ESRD patients than in control patients, further indicating elevated, more variable CRP levels. Conclusions: Our results indicate that ESRD patients have elevated CRP levels compared to healthy patients, suggesting increased inflammation and supporting CRP as a reliable biomarker to assess inflammation in patients with ESRD. The elevated CRP levels in ESRD patients demonstrate the chronic inflammatory state that is associated with renal failure and can potentially suggest higher cardiovascular risks. Our study was limited by a lack of control for confounding factors such as age and other medical conditions, and by sample size. Future studies with larger sample sizes and more inflammatory markers, such as TNF-α, should be conducted to deepen the understanding of how inflammation progresses in ESRD patients and how it affects patient outcomes.
No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.
No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.